Lipanthyl Penta 145

Lipanthyl Penta 145





Zuellig Pharma
Concise Prescribing Info
Fenofibrate (nanoparticles)
Adjunct to diet & other non-pharmacological treatment for severe hypertriglyceridaemia w/ or w/o low HDL cholesterol, mixed hyperlipidaemia when statin is contraindicated or not tolerated & mixed hyperlipidaemia in patients at high CV risk in addition to statin when triglycerides & HDL cholesterol are inadequately controlled. Reduction of diabetic retinopathy progression in patients w/ type 2 diabetes & existing diabetic retinopathy.
Dosage/Direction for Use
May be taken with or without food: Swallow whole w/ a glass of water.
Hypersensitivity to fenofibrate, peanut, arachis oil or soybean lecithin. Known gallbladder disease, photoallergy or phototoxic reaction during treatment w/ fibrates or ketoprofen. Chronic or acute pancreatitis w/ exception of acute pancreatitis due to severe hypertriglyceridemia. Severe chronic kidney disease. Hepatic insufficiency eg, biliary cirrhosis & unexplained persistent liver function abnormality.
Special Precautions
Discontinue use if symptoms indicative of hepatitis occur. Secondary cause of hyperlipidemia eg, uncontrolled type 2 DM, hypothyroidism, nephrotic syndrome, dysproteinemia, obstructive liver disease, pharmacological treatment, alcoholism; pancreatitis; predisposing factors for myopathy &/or rhabdomyolysis eg, personal or familial history of hereditary muscular disorders. Monitor transaminase levels every 3 mth during 1st 12 mth. Measure creatinine levels during 1st 3 mth & periodically thereafter. Concomitant use w/ HMG-CoA reductase inhibitor. Galactose & fructose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption, sucrase-isomaltase insufficiency. Not to be used in severe chronic kidney disease. Not recommended in hepatic impairment. Pregnancy. Not to be used during lactation. Not recommended in paed <18 yr. Elderly >70 yr.
Adverse Reactions
Increased blood homocysteine level. GI disorders eg, abdominal pain, nausea, vomiting, diarrhoea, flatulence; increased transaminases.
Drug Interactions
Enhanced oral anticoagulant effects. Increased risk of serious muscle toxicity w/ HMG-CoA reductase inhibitors & other fibrates. Reversible paradoxical HDL-cholesterol reduction w/ glitazones. Caution w/ cyclosporin, CYP2C19-, CYP2A6- & CYP2C9-metabolised drugs.
MIMS Class
Dyslipidaemic Agents
ATC Classification
C10AB05 - fenofibrate ; Belongs to the class of fibrates. Used in the treatment of hyperlipidemia.
Lipanthyl Penta 145 FC tab 145 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in